| Website | elixirpharm.com |
| Category | BioTech |
| Phone | 617-995-7000 |
| Employees | |
| Founded | 1999 |
| Description | late-stage pharmaceutical company |
| Total | $58M |
| Series C, 11/06 MPM Capital ARCH Venture Partners CDIB Ventures Jafco Ventures YFY Biotech Management Company Oxford Bioscience Partners | $46M |
| Series D, 5/09 MPM Capital ARCH Venture Partners Oxford Bioscience Partners Omega Funds Physic Ventures | $12M |
Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company’s scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.
